Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:53:03.673Z.
Calculation as of: 2026-10-06T21:53:03.673Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Revelation Biosciences, Inc.
Market Cap
$2.94M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.86M
EV/Sales Ratio
N/A
TTM Avg
10.81x
3Y Avg
12.42x
5Y Avg
14.31x
Market Cap
$3.07M
EV/Sales Ratio
N/A
TTM Avg
126.62x
3Y Avg
132.74x
5Y Avg
132.74x
Market Cap
$3.14M
EV/Sales Ratio
0.16x
TTM Avg
12.73x
3Y Avg
44.72x
5Y Avg
67.78x
Market Cap
$3.21M
EV/Sales Ratio
N/A
TTM Avg
46.50x
3Y Avg
481.93x
5Y Avg
1980.99x
Market Cap
$2.66M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.28M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $2.94M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.86M | N/A | 10.81x | 12.42x | 14.31x |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A | 126.62x | 132.74x | 132.74x |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | 0.16x | 12.73x | 44.72x | 67.78x |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A | 0.22x | 0.27x | 1.10x |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | N/A | 46.50x | 481.93x | 1980.99x |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.66M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | 10.58x | 51.17x | 75.53x | 61.28x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
